Le diagnostic se fait par culture bactérienne et tests de sensibilité aux antibiotiques.
TuberculoseRésistance aux médicaments
#2
Quels tests sont utilisés pour la TB-MR ?
Les tests incluent la culture, le test de réaction en chaîne par polymérase (PCR) et les tests de sensibilité.
Tests de diagnosticTuberculose
#3
Les symptômes aident-ils au diagnostic ?
Les symptômes comme la toux persistante et la fièvre peuvent orienter vers un diagnostic de TB.
SymptômesTuberculose
#4
Quelle est l'importance du dépistage précoce ?
Un dépistage précoce permet de commencer le traitement rapidement et de limiter la transmission.
DépistageTuberculose
#5
Les tests sanguins sont-ils fiables pour la TB-MR ?
Les tests sanguins comme l'IGRA peuvent aider, mais ne remplacent pas les cultures.
Tests sanguinsTuberculose
Symptômes
5
#1
Quels sont les symptômes de la TB-MR ?
Les symptômes incluent toux persistante, fièvre, sueurs nocturnes et perte de poids.
SymptômesTuberculose
#2
La TB-MR cause-t-elle des douleurs thoraciques ?
Oui, des douleurs thoraciques peuvent survenir en raison de l'infection pulmonaire.
Douleur thoraciqueTuberculose
#3
Les symptômes varient-ils selon les patients ?
Oui, les symptômes peuvent varier en fonction de l'état de santé et de la gravité de l'infection.
Variabilité des symptômesTuberculose
#4
La fatigue est-elle un symptôme courant ?
Oui, la fatigue est fréquente en raison de l'infection et de la réponse immunitaire.
FatigueTuberculose
#5
Les symptômes apparaissent-ils rapidement ?
Non, les symptômes peuvent se développer lentement sur plusieurs semaines ou mois.
Évolution des symptômesTuberculose
Prévention
5
#1
Comment prévenir la TB-MR ?
La prévention inclut le dépistage, le traitement préventif et la vaccination BCG.
PréventionVaccination
#2
La vaccination BCG est-elle efficace contre la TB-MR ?
La vaccination BCG offre une protection limitée contre la TB-MR, mais aide à prévenir la TB classique.
Vaccination BCGTuberculose
#3
Quelles mesures d'hygiène sont recommandées ?
Des mesures comme le port de masques et l'aération des espaces réduisent le risque de transmission.
HygièneTransmission
#4
Le dépistage est-il important pour les contacts ?
Oui, le dépistage des contacts est crucial pour identifier et traiter les cas potentiels.
DépistageContacts
#5
Les campagnes de sensibilisation aident-elles ?
Oui, elles augmentent la connaissance des symptômes et encouragent le dépistage précoce.
SensibilisationTuberculose
Traitements
5
#1
Quel est le traitement standard pour la TB-MR ?
Le traitement standard inclut des antibiotiques de seconde ligne pendant au moins 18 mois.
TraitementTuberculose
#2
Les antibiotiques de première ligne sont-ils efficaces ?
Non, les antibiotiques de première ligne ne sont pas efficaces contre la TB-MR.
AntibiotiquesRésistance aux médicaments
#3
Quels sont les effets secondaires des traitements ?
Les effets secondaires peuvent inclure nausées, douleurs abdominales et toxicité hépatique.
Effets secondairesTuberculose
#4
La durée du traitement est-elle flexible ?
Non, la durée du traitement est strictement définie pour éviter la résistance supplémentaire.
Durée du traitementTuberculose
#5
Le suivi médical est-il nécessaire pendant le traitement ?
Oui, un suivi régulier est essentiel pour surveiller l'efficacité et les effets secondaires.
Suivi médicalTuberculose
Complications
5
#1
Quelles complications peuvent survenir avec la TB-MR ?
Les complications incluent la pneumonie, l'insuffisance respiratoire et la dissémination extrapulmonaire.
ComplicationsTuberculose
#2
La TB-MR peut-elle être mortelle ?
Oui, sans traitement approprié, la TB-MR peut entraîner la mort, surtout chez les immunodéprimés.
MortalitéTuberculose
#3
Les complications affectent-elles le traitement ?
Oui, les complications peuvent rendre le traitement plus difficile et prolonger la durée de la maladie.
TraitementComplications
#4
Y a-t-il des complications à long terme ?
Oui, des complications comme des lésions pulmonaires peuvent persister même après le traitement.
Complications à long termeTuberculose
#5
Les complications sont-elles fréquentes ?
Les complications sont plus fréquentes chez les patients avec des formes avancées de la maladie.
FréquenceTuberculose
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs incluent le VIH, la malnutrition, le tabagisme et les conditions de vie précaires.
Facteurs de risqueTuberculose
#2
Le VIH augmente-t-il le risque de TB-MR ?
Oui, le VIH affaiblit le système immunitaire, augmentant le risque de TB-MR.
VIHTuberculose
#3
Les personnes âgées sont-elles plus à risque ?
Oui, les personnes âgées ont un risque accru en raison de la diminution de l'immunité.
Personnes âgéesFacteurs de risque
#4
Le voyage dans des zones endommagées est-il un risque ?
Oui, voyager dans des zones à forte prévalence de TB-MR augmente le risque d'infection.
VoyageTuberculose
#5
Les travailleurs de la santé sont-ils à risque ?
Oui, ils sont exposés à des patients infectés, augmentant leur risque de contracter la TB-MR.
Travailleurs de la santéTuberculose
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tuberculose multirésistante : Questions médicales les plus fréquentes",
"headline": "Tuberculose multirésistante : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tuberculose multirésistante : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-19",
"dateModified": "2025-04-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tuberculose multirésistante"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tuberculose",
"url": "https://questionsmedicales.fr/mesh/D014376",
"about": {
"@type": "MedicalCondition",
"name": "Tuberculose",
"code": {
"@type": "MedicalCode",
"code": "D014376",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.410.040.552.846"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tuberculose ultrarésistante aux médicaments",
"alternateName": "Extensively Drug-Resistant Tuberculosis",
"url": "https://questionsmedicales.fr/mesh/D054908",
"about": {
"@type": "MedicalCondition",
"name": "Tuberculose ultrarésistante aux médicaments",
"code": {
"@type": "MedicalCode",
"code": "D054908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.410.040.552.846.775.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tuberculose multirésistante",
"alternateName": "Tuberculosis, Multidrug-Resistant",
"code": {
"@type": "MedicalCode",
"code": "D018088",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christoph Lange",
"url": "https://questionsmedicales.fr/author/Christoph%20Lange",
"affiliation": {
"@type": "Organization",
"name": "Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany."
}
},
{
"@type": "Person",
"name": "Peize Zhang",
"url": "https://questionsmedicales.fr/author/Peize%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Pulmonary Medicine and Tuberculosis, The Third People's Hospital of Shenzhen, The National Clinical Research Center for Infectious Diseases, Shenzhen, China."
}
},
{
"@type": "Person",
"name": "Guofang Deng",
"url": "https://questionsmedicales.fr/author/Guofang%20Deng",
"affiliation": {
"@type": "Organization",
"name": "Pulmonary Medicine and Tuberculosis, The Third People's Hospital of Shenzhen, The National Clinical Research Center for Infectious Diseases, Shenzhen, China."
}
},
{
"@type": "Person",
"name": "Pennan Barry",
"url": "https://questionsmedicales.fr/author/Pennan%20Barry",
"affiliation": {
"@type": "Organization",
"name": "Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA."
}
},
{
"@type": "Person",
"name": "Stefan Niemann",
"url": "https://questionsmedicales.fr/author/Stefan%20Niemann",
"affiliation": {
"@type": "Organization",
"name": "Molecular and Experimental Mycobacteriology, Research Center Borstel Leibniz Lung Center, Borstel, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A case-control study of infections caused by",
"datePublished": "2022-07-28",
"url": "https://questionsmedicales.fr/article/35967868",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fcimb.2022.867347"
}
},
{
"@type": "ScholarlyArticle",
"name": "Errors in Surgery: A Case Control Study.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35946794",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/SLA.0000000000005664"
}
},
{
"@type": "ScholarlyArticle",
"name": "Iron status in women with infertility and controls: a case-control study.",
"datePublished": "2023-06-08",
"url": "https://questionsmedicales.fr/article/37361544",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1173100"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sleeve Gastrectomy in Septuagenarians: a Case-Control Study.",
"datePublished": "2022-07-05",
"url": "https://questionsmedicales.fr/article/35788952",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11695-022-06193-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diverticulitis Familiality: A Statewide Case-Control Study.",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37403933",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/XCS.0000000000000799"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Infections bactériennes et mycoses",
"item": "https://questionsmedicales.fr/mesh/D001423"
},
{
"@type": "ListItem",
"position": 4,
"name": "Infections bactériennes",
"item": "https://questionsmedicales.fr/mesh/D001424"
},
{
"@type": "ListItem",
"position": 5,
"name": "Infections bactériennes à Gram positif",
"item": "https://questionsmedicales.fr/mesh/D016908"
},
{
"@type": "ListItem",
"position": 6,
"name": "Infections à Actinomycetales",
"item": "https://questionsmedicales.fr/mesh/D000193"
},
{
"@type": "ListItem",
"position": 7,
"name": "Infections à Mycobacterium",
"item": "https://questionsmedicales.fr/mesh/D009164"
},
{
"@type": "ListItem",
"position": 8,
"name": "Tuberculose",
"item": "https://questionsmedicales.fr/mesh/D014376"
},
{
"@type": "ListItem",
"position": 9,
"name": "Tuberculose multirésistante",
"item": "https://questionsmedicales.fr/mesh/D018088"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tuberculose multirésistante - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tuberculose multirésistante",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tuberculose multirésistante",
"description": "Comment diagnostiquer la TB-MR ?\nQuels tests sont utilisés pour la TB-MR ?\nLes symptômes aident-ils au diagnostic ?\nQuelle est l'importance du dépistage précoce ?\nLes tests sanguins sont-ils fiables pour la TB-MR ?",
"url": "https://questionsmedicales.fr/mesh/D018088?mesh_terms=Case-Control+Studies#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tuberculose multirésistante",
"description": "Quels sont les symptômes de la TB-MR ?\nLa TB-MR cause-t-elle des douleurs thoraciques ?\nLes symptômes varient-ils selon les patients ?\nLa fatigue est-elle un symptôme courant ?\nLes symptômes apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D018088?mesh_terms=Case-Control+Studies#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tuberculose multirésistante",
"description": "Comment prévenir la TB-MR ?\nLa vaccination BCG est-elle efficace contre la TB-MR ?\nQuelles mesures d'hygiène sont recommandées ?\nLe dépistage est-il important pour les contacts ?\nLes campagnes de sensibilisation aident-elles ?",
"url": "https://questionsmedicales.fr/mesh/D018088?mesh_terms=Case-Control+Studies#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tuberculose multirésistante",
"description": "Quel est le traitement standard pour la TB-MR ?\nLes antibiotiques de première ligne sont-ils efficaces ?\nQuels sont les effets secondaires des traitements ?\nLa durée du traitement est-elle flexible ?\nLe suivi médical est-il nécessaire pendant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D018088?mesh_terms=Case-Control+Studies#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tuberculose multirésistante",
"description": "Quelles complications peuvent survenir avec la TB-MR ?\nLa TB-MR peut-elle être mortelle ?\nLes complications affectent-elles le traitement ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D018088?mesh_terms=Case-Control+Studies#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tuberculose multirésistante",
"description": "Quels sont les principaux facteurs de risque ?\nLe VIH augmente-t-il le risque de TB-MR ?\nLes personnes âgées sont-elles plus à risque ?\nLe voyage dans des zones endommagées est-il un risque ?\nLes travailleurs de la santé sont-ils à risque ?",
"url": "https://questionsmedicales.fr/mesh/D018088?mesh_terms=Case-Control+Studies#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la TB-MR ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par culture bactérienne et tests de sensibilité aux antibiotiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la TB-MR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la culture, le test de réaction en chaîne par polymérase (PCR) et les tests de sensibilité."
}
},
{
"@type": "Question",
"name": "Les symptômes aident-ils au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes comme la toux persistante et la fièvre peuvent orienter vers un diagnostic de TB."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du dépistage précoce ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un dépistage précoce permet de commencer le traitement rapidement et de limiter la transmission."
}
},
{
"@type": "Question",
"name": "Les tests sanguins sont-ils fiables pour la TB-MR ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sanguins comme l'IGRA peuvent aider, mais ne remplacent pas les cultures."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la TB-MR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent toux persistante, fièvre, sueurs nocturnes et perte de poids."
}
},
{
"@type": "Question",
"name": "La TB-MR cause-t-elle des douleurs thoraciques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs thoraciques peuvent survenir en raison de l'infection pulmonaire."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les patients ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'état de santé et de la gravité de l'infection."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme courant ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue est fréquente en raison de l'infection et de la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes peuvent se développer lentement sur plusieurs semaines ou mois."
}
},
{
"@type": "Question",
"name": "Comment prévenir la TB-MR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut le dépistage, le traitement préventif et la vaccination BCG."
}
},
{
"@type": "Question",
"name": "La vaccination BCG est-elle efficace contre la TB-MR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination BCG offre une protection limitée contre la TB-MR, mais aide à prévenir la TB classique."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures comme le port de masques et l'aération des espaces réduisent le risque de transmission."
}
},
{
"@type": "Question",
"name": "Le dépistage est-il important pour les contacts ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage des contacts est crucial pour identifier et traiter les cas potentiels."
}
},
{
"@type": "Question",
"name": "Les campagnes de sensibilisation aident-elles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles augmentent la connaissance des symptômes et encouragent le dépistage précoce."
}
},
{
"@type": "Question",
"name": "Quel est le traitement standard pour la TB-MR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement standard inclut des antibiotiques de seconde ligne pendant au moins 18 mois."
}
},
{
"@type": "Question",
"name": "Les antibiotiques de première ligne sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les antibiotiques de première ligne ne sont pas efficaces contre la TB-MR."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure nausées, douleurs abdominales et toxicité hépatique."
}
},
{
"@type": "Question",
"name": "La durée du traitement est-elle flexible ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la durée du traitement est strictement définie pour éviter la résistance supplémentaire."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il nécessaire pendant le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller l'efficacité et les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la TB-MR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la pneumonie, l'insuffisance respiratoire et la dissémination extrapulmonaire."
}
},
{
"@type": "Question",
"name": "La TB-MR peut-elle être mortelle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement approprié, la TB-MR peut entraîner la mort, surtout chez les immunodéprimés."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles le traitement ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent rendre le traitement plus difficile et prolonger la durée de la maladie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des lésions pulmonaires peuvent persister même après le traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont plus fréquentes chez les patients avec des formes avancées de la maladie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le VIH, la malnutrition, le tabagisme et les conditions de vie précaires."
}
},
{
"@type": "Question",
"name": "Le VIH augmente-t-il le risque de TB-MR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le VIH affaiblit le système immunitaire, augmentant le risque de TB-MR."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru en raison de la diminution de l'immunité."
}
},
{
"@type": "Question",
"name": "Le voyage dans des zones endommagées est-il un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones à forte prévalence de TB-MR augmente le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les travailleurs de la santé sont-ils à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont exposés à des patients infectés, augmentant leur risque de contracter la TB-MR."
}
}
]
}
]
}
Pulmonary Medicine and Tuberculosis, The Third People's Hospital of Shenzhen, The National Clinical Research Center for Infectious Diseases, Shenzhen, China.
Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Pulmonary Medicine and Tuberculosis, The Third People's Hospital of Shenzhen, The National Clinical Research Center for Infectious Diseases, Shenzhen, China.
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Shanghai Institute of Infectious Disease and Biosecurity and Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Infections caused by antimicrobial-resistant bacteria are a significant cause of death worldwide, and carbapenemase-producing bacteria are the principal agents. New Delhi metallo-beta-lactamase-1 prod...
A retrospective case-control study with patients hospitalized from January 2012 to February 2018 at the Hospital Civil de Guadalajara "Fray Antonio Alcalde" was designed. During this period, 139 patie...
One hundred and thirty-nine case patients with a KP-NDM-1 isolate and 486 control patients were analyzed. In the case group, acute renal failure was a significant comorbidity, hospitalization days wer...
In this study, the previous use of antibiotics, the use of a urinary catheter, the use of a central venous catheter, the use of mechanical ventilation, and ICU stay were shown to be predictors of infe...
While errors can harm patients they remain poorly studied. This study characterized errors in the care of surgical patients and examined the association of errors with morbidity and mortality....
Errors have been reported to cause <10% or >60% of adverse events. Such discordant results underscore the need for further exploration of the relationship between error and adverse events....
Patients with operations performed at a single institution and abstracted into the American College of Surgeons National Surgical Quality Improvement Program from January 1, 2018, to December 31, 2018...
Of 1899 patients, 170 were defined as cases who experienced a morbidity or mortality. The majority of cases (n=93; 55%) had at least 1 error; of the 329 matched control patients, 112 had at least 1 er...
Errors in surgical care were associated with postoperative morbidity. Reducing errors requires measurement of errors....
Iron deficiency is a common problem in subfertile women. The influence of iron status on unexplained infertility is unknown....
In a case-control study, 36 women with unexplained infertility and 36 healthy non-infertile controls were included. Parameters of iron status including serum ferritin and a serum ferritin <30 µg/dL se...
Women with unexplained infertility demonstrated a lower transferrin saturation (median 17.3%, IQR 12.7-25.2 versus 23.9%, IQR 15.4-31.6;...
Ferritin levels <30µg/L were associated with unexplained infertility and might be screened in the future. Further studies with a focus on iron deficiency and iron treatment on women with unexplained i...
There are few studies published referring to bariatric surgery in patients older than 70 years. The aim of this study is to evaluate whether there are benefits to performing sleeve gastrectomy (SG) in...
Data were retrospectively collected from a Private Clinic's electronic medical records of patients undergoing SG between June 2017 and September 2020. Inclusion criteria were patients older than 70 ye...
Fifty patients were included in the study. Both groups were similar regarding gender, weight, BMI, and presence of DM. The 30-day morbidity and mortality were similar between the groups. The patients ...
The sleeve gastrectomy surgery performed in patients over 70 years of age is safe. The early results suggest similar benefits regarding weight loss and improvement of comorbidities to those having SG ...
The etiology of diverticulitis is multifactorial and poorly understood. We estimated the familiality of diverticulitis using the Utah Population Database, a statewide database linking medical records ...
We identified patients with diverticulitis diagnosed between 1998 and 2018 and age- and sex-matched controls in the Utah Population Database. Risk of diverticulitis in family members of patients and c...
The study population included 9,563 diverticulitis patients (with 229,647 relatives) and 10,588 controls (with 265,693 relatives). Relatives of patients were more likely to develop diverticulitis (inc...
Our results indicate that the first-, second-, and third-degree relatives of diverticulitis patients are at elevated risk of developing diverticulitis. This information may aid surgeons in counseling ...
This study aimed to investigate the clinical and laboratory as well as radiological features of spondyloarthritis (SpA) patients with thrombocytosis and to explore risk factor for thrombocytosis in Sp...
A total of 145 patients with SpA were included in this study, and non-thrombocytosis was identified in 76 patients while thrombocytosis was found in 69 patients, 38 out of the 69 patients received ant...
The proportion of hip involvement (60.86% vs 36.84%, p = 0.004), bath ankylosing spondylitis disease activity index score (4.24 ± 0.55 vs 3.69 ± 0.67, p < 0.001), erythrocyte sedimentation rate (62.22...
SpA patients with thrombocytosis have a higher proportion of hip involvement and disease activity compared to non-thrombocytosis SpA patients. The potential risk factors for thrombocytosis in SPA pati...
Recent studies of the vaginal microbiome have led to a better understanding of the microbiota and interactions with the host environment, however the role of the vaginal microbiome in vestibulodynia r...
This study aims to investigate and examine differences in the bacterial and fungal microbiome among patients with vestibulodynia and healthy controls....
A case-control study was conducted examining the vaginal microbiome of 29 patients with vestibulodynia and 26 controls through Stony Brook University Obstetrics and Gynecology ambulatory clinic. Exclu...
Principal component analysis (PCA) and linear discriminant analysis effect size (LefSe) were used to identify differences in relative abundance of operational taxonomic units (OTUs) for the vaginal mi...
Lactobacillus species were dominant amongst both cases and controls. PCA of 16S and ITS OTUs did not show significant differences in microbiome composition between vestibulodynia patients and controls...
Additional studies are needed to further assess the clinical significance of these findings....
Strengths of this study include ITS amplicon sequence analysis for fungal species diversity. Limitations of this study include small sample size and lack of racial diversity....
Our study did not find significant differences in composition or diversity between the vaginal microbiomes of cases of vestibulodynia and controls; however, the data suggests differences in abundance ...
Varied reports suggest a contentious relationship of bladder malignancy with pioglitazone in patients with type 2 diabetes....
To study an association (prevalence and predictors) of bladder malignancy with pioglitazone therapy in Asian-Indian type 2 diabetes patients....
In this observational multicenter study, type 2 diabetic patients attending out-patient diabetes-clinic were evaluated. A detailed history of anti-diabetic medication, dose, duration, pioglitazone usa...
A total of 8000 patients were screened out of which 1560 were excluded. Among 6440 included patients, 1056 (16.3%) patients were in group A and 5384 (83.6%) group B. Patients on pioglitazone were olde...
Pioglitazone use in Asian-Indians is not associated with an increased bladder cancer risk. However, pioglitazone should be restricted in individuals with history of hematuria. Age more than 58 years i...
Multiple chemical sensitivity (MCS) is a chronic condition characterized by the appearance of symptoms caused by exposure to chemical compounds that are tolerable for the general population. It mainly...
Stroke is the leading cause of mortality in China. DNA methylation has essential roles in multiple diseases, but its association with stroke was barely studied. We hereby explored the association betw...
The association was discovered in a hospital-based case-control study (cases/controls = 190:190) and further validated in a prospective nested case-control study including 139 cases who developed stro...
In our study, altered HTRA1 methylation was associated with stroke at clinical and preclinical stages and thus may provide a potential biomarker in the blood for the risk evaluation and preclinical de...
